Home | Articles
Published on:June 2021
Indian Journal of Pharmaceutical Education and Research, 2021; 55(2s):s605-s615
Analysis | doi:10.5530/ijper.55.2s.133

Assessment of Toxicity and Drug-Drug Interaction of Combination Therapy Prescribed by Physicians/ Clinicians for Treatment of Diabetes using Experimental Animals


Authors and affiliation (s):

Hemlata Dewangan1, Raj Kumar Tiwari2, Vikas Sharma1, Shiv Shankar Shukla1, Ravindra Kumar Pandey1,*

1Department of Pharmacology, Columbia Institute of Pharmacy, Raipur, Chhattisgarh, INDIA.

2Columbia Institute of Pharmacy, Raipur, Chhattisgarh, INDIA.

Abstract:

Purpose: The management of diabetes associated with hyperlipidemia is a challenge not only to the physician but also to medical fraternity. Hence most of the physicians prefer to prescribe antihyperglycemic drug along with some lipid lowering agent. The present study is aimed to find out toxicity and drug interaction of combination therapy of hypoglycemic agents (Glimepride, Metformin) withhypolipidemic drugs (Atovastatin + Fenofibrate). Materials and Methods: Young healthy adult Albino Wister rats (150-180 g) were used in the study. The experimental animals we reassessed for acute toxicity study and ant diabetic activity. The drug-drug interaction was also evaluated by changes in physiological, hematological parameters and histopathology of different tissues. Results: The result of acute toxicity revealed that there was a change in body weight in the animal treated with hypoglycemic agents (Glimepride, Metformin) withhypolipidemic drugs (Atovastatin + Fenofibrate). Water, food consumption has not been varied with greater extent in all groups of animals. Mild changes were marked inhemoglobin, neutrophils, - platelet count. Conclusion: The combination of drugs showed mild change in the effect of Glimepride + Metformin alone and in combination with Atorvastatin + Fenofibrate. Other factors showed no significant effect which proves that there is no drug interaction.

Key words: Drug interaction, Diabetes, Toxicity, Combination therapy, Metformin, Atorvastatin.

 




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the 2019 Release of Journal Citation Reports (source: 2018 Web of Science Data).

 

Impact Factor® as reported in the 2018 Journal Citation Reports® (Clarivate Analytics, 2019): 0.425

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs